Skip to main content
. 2023 Jan 25;36(2):ivad018. doi: 10.1093/icvts/ivad018

Table 1:

Demographical, clinical, periprocedural and pathological data

Variable VATS-LL (n = 45) VATS-BS (n = 16) P-Value
RLL, n (%) 26 (57.8)
LLL, n (%) 19 (42.2)
RBS, n (%) 8 (50)
LBS, n (%) 8 (50)
Sex male, n (%) 27 (60) 12 (75) <0.99
Age, median (IQR) 68 (11) 67 (10) 0.8
ASA score, n (%) 0.556
 1 6 (13.3) 4 (25)
 2 23 (51.1) 7 (43.8)
 3 16 (35.6) 5 (31.3)
PS, n (%) 0.621
 0 19 (42.2) 5 (31.3)
 1 19 (42.2) 7 (43.8)
 2 7 (15.6) 4 (25)
COPD, n (%) 9 (20) 4 (25) 0.675
CCI, median (range) 1 (0–3) 2 (0–3) 0.725
Smoking history, n (%) 0.44
 Never smoker 7 (15.6) 1 (6.3)
 Former smoker 18 (40) 9 (56.3)
 Actual smoker 20 (44.4) 6 (37.5)
NSCLC clinical stage, n (%) 0.07
 1a 34 (75.5) 16 (100)
 1b 11 (24.5)
Maximun tumour diameter, median (IQR) 20 (15) 18 (9) 0.35
Minimum tumour diameter, median (IQR) 15 (10) 13 (5) 0.48
Preoperative PFTs, n (%)
 FEV1 l 1.68 (0.73) 1.825 (0.58) 0.9
 FEV1% 82.5 (14) 96 (28.25) 0.078
 FVC l 2.66 (0.86) 2.63 (1) 0.49
 FVC% 99 (28) 111.5 (18.4) 0.3
 DLCO% 73.5 (20) 69.5 (40.75) 0.3
Postoperative PFTs, n (%)
 FEV1 l 1.47 (0.37) 1.51 (0.65) 0.26
 FEV1% 72.5 (10) 79.5 (27.5) 0.016
 FVC l 2.03 (0.84) 2.61 (1.12) 0.056
 FVC% 86 (11) 96.5 (29) 0.015
 DLCO% 63 (18.5) 67 (21.5) 0.22

ASA: American Society of Anesthesiologists; CCI: Charlson Comorbidity Index; COPD: chronic obstructive pulmonary disease; DLCO: diffusing capacity for carbon monoxide; FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; IQR: interquartile range; LBS: left basal segmentectomy; LLL: left lower lobectomy; NSCLC: non-small-cell lung cancer; PFTs: pulmonary function tests; PS: performance status score; RBS: right basal segmentectomy; RLL: right lower lobectomy; VATS-BS: video-assisted thoracoscopic surgery basal segmentectomy; VATS-LL: video-assisted thoracoscopic surgery lower lobectomy.